Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%
Information source: Innovative Medical
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Vitrectomy
Intervention: Nepafenac (Drug); Ketorolac LS, Bromfenac (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Innovative Medical Official(s) and/or principal investigator(s):
Jeffrey Heier, MD, Principal Investigator, Affiliation: Ophthalmic Consultants of Boston
Overall contact:
melissa Earl, Phone: 951-786-0403, Email: m.earl@imedsonline.com
Summary
To compare the penetration of three different NSAIDs.
Clinical Details
Study design: Randomized, Double-Blind, Active Control, Parallel Assignment
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females scheduled to undergo Vitrectomy surgery
- Likely to complete all study visits and able to provide informed consent
- Visual potential of 20/25 or better
Exclusion Criteria:
- Known contraindications to any study medication or ingredients
- Active ocular diseases or uncontrolled systemic disease
- Active ocular allergies
Locations and Contacts
melissa Earl, Phone: 951-786-0403, Email: m.earl@imedsonline.com
Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, United States; Recruiting
Jeffrey Heier, MD, Phone: 617-367-4800, Email: jsheier@eyeboston.com
Additional Information
Last updated: June 11, 2007
|
